GHRP-2 / 5 mg

Description

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as Pralmorelin, is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) family. Like GHRP-6, it stimulates growth hormone release through activation of the growth hormone secretagogue receptor (GHSR-1a), commonly known as the ghrelin receptor.

Among the classic GHRPs, GHRP-2 has become particularly well known because of its high potency in stimulating pulsatile growth hormone secretion. This has made it a cornerstone compound in endocrine research exploring the physiology of the GH/IGF-1 axis and neuroendocrine regulation.

Why GHRP-2 matters in endocrine research

One of GHRP-2’s defining characteristics is its robust activation of the ghrelin receptor, resulting in a pronounced pulsatile release of growth hormone.

Published research has investigated GHRP-2 in relation to:

• growth hormone secretion
• IGF-1 physiology
• endocrine regulation
• ghrelin receptor biology
• pituitary function
• neuroendocrine signalling
• appetite physiology
• metabolic regulation

Unlike GHRP-6, whose literature frequently emphasises appetite regulation, GHRP-2 is more commonly recognised for its endocrine potency and GH-releasing characteristics.

How GHRP-2 works

Rather than stimulating the GHRH receptor, GHRP-2 activates the growth hormone secretagogue receptor (GHSR-1a), producing physiological pulses of growth hormone through the ghrelin signalling pathway.

Published research has explored its relationship with:

Growth hormone secretion

GHRP-2 is one of the most potent synthetic secretagogues investigated for stimulating pulsatile GH release, producing rapid endocrine responses in both laboratory and human studies.

IGF-1 regulation

Repeated GH pulses have been investigated for their downstream influence on insulin-like growth factor-1 physiology and endocrine adaptation.

Neuroendocrine signalling

Researchers have examined how GHRP-2 interacts with hypothalamic and pituitary regulation of hormone secretion.

Ghrelin receptor biology

Because GHRP-2 directly activates GHSR-1a, it has become an important experimental tool for understanding ghrelin receptor function beyond endogenous ghrelin itself.

Why GHRP-2 is widely investigated in GH physiology research

Among the classic growth hormone secretagogues, GHRP-2 is recognised for its strong and reproducible GH-releasing profile.

Published studies have investigated:

• pulsatile GH secretion
• pituitary function
• endocrine physiology
• IGF-1 regulation
• growth hormone deficiency testing
• neuroendocrine responses
• ghrelin receptor activation

Because of this robust endocrine activity, GHRP-2 has served as a reference compound in many studies evaluating growth hormone secretagogues and their interaction with the GH/IGF-1 axis.

Human and preclinical research

GHRP-2 has been investigated extensively in both laboratory models and human studies over several decades.

Published research includes endocrine physiology, diagnostic stimulation testing, growth hormone secretion, ghrelin receptor pharmacology and appetite regulation. Compared with many newer secretagogues, GHRP-2 has one of the longest research histories within the GHS class.

How GHRP-2 differs from other GH secretagogues

GHRP-2

• High-potency GH secretagogue
• Strong pulsatile GH release
• Endocrine physiology
• Ghrelin receptor research

GHRP-6

• Ghrelin receptor agonist
• Greater emphasis on appetite research
• Gastrointestinal physiology
• Endocrine signalling

Ipamorelin

• More selective ghrelin receptor agonist
• Minimal appetite stimulation
• Cleaner hormonal profile
• Growth hormone research

CJC-1295 (No DAC)

• GHRH analogue
• Different receptor pathway
• Frequently investigated alongside GHRPs because of complementary mechanisms.

Published safety observations

Published human studies have generally reported transient increases in growth hormone following GHRP-2 administration, together with endocrine changes consistent with ghrelin receptor activation. As with other classic growth hormone secretagogues, transient increases in prolactin, cortisol and appetite have also been described in some research settings.

Product characteristics

Application: laboratory and analytical research
Use restriction: not for human consumption; not for medical, veterinary or cosmetic use
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Purity: ≥98% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Molecular formula: C₄₇H₅₈N₁₀O₇
Molecular weight: 818.0 g/mol
Sequence: Gly-D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2

Storage: unopened lyophilized vials are best stored refrigerated at 2–8°C, which is the storage method confirmed by our manufacturing partner and suitable for up to 24 months. Refrigeration is preferred because it minimizes unnecessary freeze–thaw cycles during routine handling. If substantially longer-term storage is required, unopened lyophilized vials may also be kept frozen. Once reconstituted, always store at 2–8°C and do not freeze.

Reconstitution and handling

ГХРП-2 is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with bacteriostatic water before use. To help preserve structural integrity, add the chosen solvent slowly against the inside wall of the vial rather than directly onto the peptide cake, and avoid vigorous shaking. Gentle swirling is generally sufficient once the peptide has fully dissolved. Standard laboratory practice also includes allowing refrigerated vials to reach room temperature before reconstitution to minimise condensation inside the vial.

For other solvent selection, concentration planning and storage guidance, see the full Peptide Reconstitution Guide and Reconstitution Calculator.

Key published studies

• Laferrère B, Abraham C, Russell CD, et al. Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. Journal of Clinical Endocrinology & Metabolism, 2005.

A landmark human study confirming robust GH secretion following GHRP-2 administration while also demonstrating activation of ghrelin-related appetite pathways.

• Yin Y, Li Y, Zhang W. The Growth Hormone Secretagogue Receptor: Its Intracellular Signalling and Physiological Function. International Journal of Molecular Sciences, 2014.

A comprehensive review of GHSR biology, ghrelin signalling and the mechanisms through which peptides such as GHRP-2 regulate endocrine function.

• Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs). Clinical Science, 2017.

A broad review summarising the pharmacology, physiology and research applications of the GHRP family, including GHRP-2.

• Cheng J, et al. Growth Hormone Releasing Peptides: A Comparison of the Activity of GHRP-2 and GHRP-6. Life Sciences, 1997.

One of the classic comparative studies describing similarities and differences between GHRP-2 and GHRP-6 in growth hormone secretion.

Frequently Asked Questions

What is GHRP-2?

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as Pralmorelin, is a synthetic hexapeptide that activates the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. It is widely investigated in endocrine research involving pulsatile growth hormone secretion, pituitary physiology, IGF-1 regulation and neuroendocrine signalling.

How does GHRP-2 stimulate growth hormone release?

Unlike GHRH analogues, GHRP-2 stimulates growth hormone secretion by activating the ghrelin receptor (GHSR-1a). This receptor is naturally involved in regulating growth hormone release through the ghrelin signalling pathway. Published studies have shown that GHRP-2 produces robust pulsatile GH responses, making it one of the best-characterised growth hormone secretagogues in endocrine research.

How does GHRP-2 differ from GHRP-6?

Both peptides belong to the same family and activate the GHSR-1a receptor, but they are commonly investigated for different reasons. GHRP-2 is generally recognised for producing stronger growth hormone release, whereas GHRP-6 is more closely associated with appetite and ghrelin-related physiology because of its more pronounced orexigenic effects. Both continue to play important roles in growth hormone and endocrine research.

How does GHRP-2 differ from Ipamorelin?

Both peptides stimulate growth hormone secretion through the ghrelin receptor, but Ipamorelin is more selective, with relatively limited effects on other pituitary hormones. GHRP-2 has traditionally been investigated as a more potent growth hormone secretagogue, while Ipamorelin is often chosen for research focused on selective ghrelin receptor activation.

Can GHRP-2 be combined with CJC-1295 in research?

Yes. In experimental endocrine research, GHRP-2 and CJC-1295 (No DAC) are frequently investigated together because they stimulate growth hormone release through different physiological pathways. GHRP-2 activates the ghrelin receptor, while CJC-1295 acts through the GHRH receptor. This complementary biology has made the combination a common research model for studying pulsatile GH secretion.

What research areas commonly investigate GHRP-2?

Published studies have investigated GHRP-2 in relation to growth hormone secretion, endocrine physiology, pituitary function, IGF-1 regulation, ghrelin receptor biology, neuroendocrine signalling, metabolic regulation and diagnostic growth hormone stimulation testing.

Is this product intended for human use?

No. GHRP-2 supplied by LIFE Peptide is provided strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published studies summarises the current scientific literature relating to the GHRP-2 molecule rather than the intended use of this product.

Related research context

GHRP-2 belongs to the growth hormone secretagogue research class, which includes peptides investigated for endocrine signaling, GH-axis modulation, and pulsatile hormone release mechanisms.
For a broader overview of GH signaling pathways and comparative peptide mechanisms, see our Growth hormone peptides research guide.
Researchers studying GH-axis interaction may also examine:

Ipamorelin
CJC-1295 (no DAC)
Tesamorelin
GHRP-6

Browse all compounds in the Growth hormone secretagogues category.

Researchers investigating endocrine regulation may also explore compounds in the Metabolic research category, including GLP-1 and multi-pathway incretin agonists.

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.